US4923699A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Eye treatment suspension
Assignee: Individual
•
Filing: 1988-06-03
•
Granted: 1990-05-08
•
Expires: 2008-06-03
Abstract
Abstract An ophthalmic treatment system is provided which includes three-dimensional particles of bioerodible material suspended in a liquid carrier or ointment carrier having a pH acceptable to the eye. The particles are at least 0.5 mm in greatest dimension and are not greater than 0.4 mm to 0.7 mm in smallest dimension when disposed in the ocular environment. The treatment system provides reliable, prolonged continuous treatment without irritating the eye.
Inventors
- 👤 Herbert E. Kaufman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 21:53
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1658
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
78 words
An opthalmic treatment system comprising: three dimensional particles of bioerodible material being at least 0.5 mm and in the range of 1 to 2 mm in greatest dimension, being no greater than 0.4 mm to 0.7 mm in smallest dimension when disposed in an ocular environment, and at least 0.5 mm in the remaining dimension and one of a liquid carrier and an ointment carrier having a pH acceptable to the eye in which said particles are suspended.
Claim 2
Dependent Claim
78 words
An opthalmic treatment system comprising: three dimensional particles of bioerodible material being at least 0.5 mm and in the range of 1 to 2 mm in greatest dimension, being no greater than 0.4 mm to 0.7 mm in smallest dimension when disposed in an ocular environment, and at least 0.5 mm in the remaining dimension and one of a liquid carrier and an ointment carrier having a pH acceptable to the eye in which said particles are suspended.
Claim 3
Dependent Claim
31 words
A system as in claim 1, wherein said bioerodible material is at least one member selected from the group consisting of collagen, gelatin, polyvinyl alcohol, polymerized methycellulose and methyl cellulose derivatives.
Claim 4
Dependent Claim
20 words
A system as in claim 1, further comprising at least one ophthalmic drug included in said particles of bioerodible material.
Claim 5
Dependent Claim
18 words
A system as in claim 3, wherein said at least one ophthalmic drug is encapsulated in said particles.
Claim 6
Dependent Claim
18 words
A system as in claim 3, wherein said at least one ophthalmic drug is dispersed throughout said particles.
Claim 7
Dependent Claim
31 words
A system as in claim 3, wherein said bioerodible material is at least one member selected from the group consisting of collagen, gelatin, polyvinyl alcohol, polymerized methycellulose and methyl cellulose derivatives.
Claim 8
Dependent Claim
43 words
A system as in claim 3, wherein said at least one ophthalmic drug is encapsulated within a coating of said bioerodible material, with said ophthalmic drug released in the eye when said coating of bioerodible material erodes in response to the ocular environment.
Claim 9
Dependent Claim
38 words
A System as in claim 3, wherein said at least one ophthalmic drug is dispersed throughout said bioerodible material, with said ophthalmic drug continually released in the eye as said particles erode in response to the ocular environment.
Claim 10
Dependent Claim
24 words
A system as in claim 1, wherein said particles have a smallest dimension no greater than 0.5 mm in said suspension prior to administration.
Claim 11
Dependent Claim
44 words
A system as in claim 1, wherein said particles are in a soft, malleable form such that the particles are deformed by the eyelid when placed in the ocular environment between the eyelid and the eye and are comfortable if disposed between the eyelids.
Claim 12
Dependent Claim
15 words
A system as in claim 10, wherein said particles are in a soft, semi-solid form.
Claim 13
Dependent Claim
51 words
A system as in claim 10, wherein said particles are greater than about 0.4 mm to 0.7 mm in smallest dimension in said suspension prior to administration and are compressed to no more than 0.5 mm in smallest dimension when disposed in the ocular environment between the eyelid and the eye.
Claim 14
Dependent Claim
15 words
A system as in claim 12, wherein said particles are in a soft, semi-solid form.
Claim 15
Dependent Claim
33 words
A system as in claim 1, wherein said particles are in the form of at least one of the group selected from spherical, hemispherical, elongated cylindrical, cubical, rectangular, elongated rectangular and rounded disc-shaped.
Claim 16
Dependent Claim
36 words
A system as in claim 1, wherein said particles are in a soft semi-solid, malleable form, with said particles conforming to the undersurface of the eyelid after administration and being comfortable if disposed in between eyelids.
Claim 17
Dependent Claim
15 words
A system as in claim 1, wherein said greatest dimension is greater than 1 mm.
Claim 18
Dependent Claim
24 words
A system as in claim 1, wherein said particles of bioerodible material are hydrated at the time of administration thereby providing soft malleable particles.
Claim 19
Dependent Claim
17 words
A system as in claim 1, wherein said particles of bioerodible material are free of drug additive.
Claim 20
Dependent Claim
23 words
A system as in claim 1, wherein said particles of bioerodible material provide moisture and lubrication to the eye when said particles erode.
Claim 21
Dependent Claim
37 words
A system as in claim 19, wherein said bioerodible material of said particles are in a form such that said bioerodible material is released in the eye as said particles erode in response to the ocular environment.
Claim 22
Dependent Claim
17 words
A system as in claim 19, wherein at least a portion of said bioerodible material is lipid.
Claim 23
Dependent Claim
23 words
A system in claim 21, wherein said lipid is selected from at least one of the following group: licithin, cholesterol, and fatty alcohols.
Claim 24
Dependent Claim
15 words
A system as in claim 1, wherein said particles include an aqueous solution encapsulated therein.
Claim 25
Dependent Claim
84 words
Method of treating the eye comprising: applying directly to the eye a suspension of three-dimensional particles of bioerodible material being at least 0.5 mm and in the range of 1 to 2 mm in greatest dimension, being no greater than about 0.4 to 0.7 mm in smallest dimension when disposed in a ocular environment, and at least 0.5 mm in the remaining dimension, said particles being suspended in one of a liquid carrier and an ointment carrier having a pH acceptable to the eye.
Claim 26
Dependent Claim
84 words
Method of treating the eye comprising: applying directly to the eye a suspension of three-dimensional particles of bioerodible material being at least 0.5 mm and in the range of 1 to 2 mm in greatest dimension, being no greater than about 0.4 to 0.7 mm in smallest dimension when disposed in a ocular environment, and at least 0.5 mm in the remaining dimension, said particles being suspended in one of a liquid carrier and an ointment carrier having a pH acceptable to the eye.
Claim 27
Dependent Claim
60 words
A method as in claim 24, wherein the particles are malleable such that the particles are deformed by pressure between the eyelid and the eye and wherein said applying of the suspension includes directing the suspension into an area of the ocular environment between an eyelid and the eye such that said particles are deformed to conform to the eye.
Claim 28
Dependent Claim
40 words
A method as in claim 25, wherein said deforming by the eyelid reduces the particle size such that the smallest particle size dimension under the eyelid is less than the smallest particle size dimension in the suspension prior to administration.
Claim 29
Dependent Claim
48 words
A method as in claim 25, wherein said particles are greater than about 0.4 mm to 0.7 mm in smallest dimension in said suspension prior to administration and are compressed to no more than 0.5 mm in smallest dimension by the pressure between the eyelid and the eye.
Claim 30
Dependent Claim
48 words
A method as in claim 24, wherein said applying of said suspension includes dispensing said suspension out of one of the following containers: a dropper, a syringe, a compressible plastic cylinder, a unit dose dropper, and a tube with a suitable orifice for dispensing ointment into the eye.
Claim 31
Dependent Claim
21 words
A method as in claim 24, wherein said applying of said suspension includes dispensing said suspension into the lower fornix region.
Claim 32
Dependent Claim
23 words
A method as in claim 24, wherein said applying of said suspension includes using particles having at least one ophthalmic drug included therein.
Claim 33
Dependent Claim
31 words
A method as in claim 24, wherein said applying of said suspension includes using particles which provide moisture and lubrication to the eye when said particles erode in said ocular environment.
Claim 34
Dependent Claim
21 words
A method as in claim 31, wherein said applying of said suspension includes using particles which are free of drug additive.
Claim 35
Dependent Claim
25 words
A method as in claim 24, wherein said suspension is applied from a container having an eye dropper extension and said carrier being a viscous.
References Cited (Backward Citations)
US3826258A
Cited
US3845201A
Cited
US3968201A
Cited
US3914402A
Cited
US4001388A
Cited
US4179497A
Cited
US4115544A
Cited
US4164559A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-07 | 1993-11-06 | 1994-05-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-07 | 1997-11-06 | 1998-05-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-07 | 2001-11-06 | 2002-05-08 | $7700.00 | Window Closed / Lapsed |